Kontron finds a buyer

Article

U.K. ultrasound and patient monitoring firm Kontron Instruments found a buyer last month, only weeks after going into receivership. The company was purchased Feb. 5 by Innermail Ltd., a subsidiary of Charterhouse Group International, a private equity

U.K. ultrasound and patient monitoring firm Kontron Instruments found a buyer last month, only weeks after going into receivership. The company was purchased Feb. 5 by Innermail Ltd., a subsidiary of Charterhouse Group International, a private equity company based in New York City.

At the time it went into receivership, Kontron owed roughly $8 million to its creditors. Its assets were intellectual property rights to its monitoring products, an electronic assembly plant, raw materials, and stock, according to Kontron's receiver, KPMG, an international accounting firm also based in the U.K. (SCAN 2/17/99). Ninety Kontron employees lost jobs as a result of the company's failure, although KPMG anticipates that several of these employees will be hired by Innermail. Charterhouse Group was unavailable for comment on the Kontron purchase.

Recent Videos
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Related Content
© 2025 MJH Life Sciences

All rights reserved.